

LSN2839567

Chemical Properties


CAS No. : 1231930-57-6

Formula: C₂₅H₂₈F₂N₈

Molecular Weight: 478.54

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	LSN2839567 (Abemaciclib metabolite M2) is the active metabolite of Abemaciclib, a potent CDK4 and CDK6 inhibitor (IC ₅₀ s: 1-3 nM) with anticancer activity. LSN2839567 inhibits CDK9. LSN2839567 inhibits cell growth and cell cycle progression in a concentration-dependent manner. cell growth and cell cycle progression in a concentration-dependent manner and can be used to study breast and lung cancer.
Targets(IC ₅₀)	CDK, Drug Metabolite
In vivo	Abemaciclib metabolite M2 is a plasma metabolite of Abemaciclib with anticancer activity[2].

Solubility Information

Solubility	DMSO: 1 mg/mL (2.09 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.09 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0897 mL	10.4484 mL	20.8969 mL
5 mM	0.4179 mL	2.0897 mL	4.1794 mL
10 mM	0.209 mL	1.0448 mL	2.0897 mL
50 mM	0.0418 mL	0.209 mL	0.4179 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Teresa Burke, et al. Abstract 2830: The major human metabolites of abemaciclib are inhibitors of CDK4 and CDK6. Cancer Research. July 2016, 76 (14).

Maeda A, et al. Effects of ABCB1 and ABCG2 Polymorphisms on the Pharmacokinetics of Abemaciclib Metabolites (M2, M20, M18). Anticancer Res. 2023 Mar;43(3):1283-1289.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481